| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/24/2003 | WO2002088180A3 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 04/24/2003 | WO2002087614A3 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen |
| 04/24/2003 | WO2002079429A3 Anti-muc-1 single chain antibodies for tumor targeting |
| 04/24/2003 | WO2002065129A3 Epitopic sequences for diagnosing infection by chlamydia trachomatis |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002064154A3 Methods and compositions for inhibiting hiv-coreceptor interactions |
| 04/24/2003 | WO2002060938A3 Haemophilus influenza basb212 polynucleotides, polypeptides and use thereof |
| 04/24/2003 | WO2002060921A9 Enhancement of immune response to vaccine by interferon alpha |
| 04/24/2003 | WO2002055552A3 Soluble cyclic analogues of beta amyloid peptide |
| 04/24/2003 | WO2002050120A3 High affinity antibodies |
| 04/24/2003 | WO2002030980A3 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 04/24/2003 | WO2002018585A8 Packaging of positive-strand rna virus replicon particles |
| 04/24/2003 | WO2002012447A3 Isolation and use of solid tumor stem cells |
| 04/24/2003 | WO2002009751A8 COMPOSITIONS FOR INDUCING SELF-SPECIFIC ANTI-IgE ANTIBODIES AND USES THEREOF |
| 04/24/2003 | US20030078410 Expression vector for use in the transfer of genes and preparation of vaccines |
| 04/24/2003 | US20030078409 Nucleotide sequences coding polypeptide for use in the treatment of respiratory system, asthmatic and inflammatory bowel diseases |
| 04/24/2003 | US20030078398 Recombinant DNA molecules encoding aminopeptidase enzymes and their use in the preparation of vaccines against helminth infections |
| 04/24/2003 | US20030078396 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 04/24/2003 | US20030078390 Tissue cement proteins from Rhipicephalus appendiculatus |
| 04/24/2003 | US20030078389 Gamma-heregulin |
| 04/24/2003 | US20030078386 Antibody for use in the treatment of viral, gastrointestinal, autoimmune and cell proiferative disorders |
| 04/24/2003 | US20030078378 Blocking expression of virulence factors in S. aureus |
| 04/24/2003 | US20030078373 Chaperone fragments |
| 04/24/2003 | US20030078302 As carriers for delivering active agents such as peptides, drugs by administration, such as oral, subcutaneous, sublingual, and intranasal administration |
| 04/24/2003 | US20030078223 Administering to individual first dose of composition comprising an immunomodulatory nucleic acid and after suitable time administering second dose of composition comprising an immunomodulatory nucleic acid; antiasthmatics |
| 04/24/2003 | US20030078208 Oral tolerance induction by collagen to prevent allograft rejection |
| 04/24/2003 | US20030078201 Composition containing peptide and carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, and three preferably consecutive amino acids of peptide are identical to three amino acids of allergenic protein |
| 04/24/2003 | US20030077841 Therapeutic potential of immunoglobulin preparations |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077809 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer, inflammation and skin disorders |
| 04/24/2003 | US20030077802 Human PRL1 phosphatase |
| 04/24/2003 | US20030077738 Nucleotide sequences coding polypeptide for use in the treatment of immunological disorders |
| 04/24/2003 | US20030077676 Anti-MUC-1 single chain antibodies for tumor targeting |
| 04/24/2003 | US20030077641 Methods of suppressing microglial activation and systemic inflammatory responses |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077618 Methods for the early diagnosis of ovarian cancer |
| 04/24/2003 | US20030077585 Nucleotide sequences coding polypeptide for use in the diagnosis, detection, prevention and treatment of bacterial infection |
| 04/24/2003 | US20030077582 Methods for diagnosing and monitoring malignancies by screeining gene copy numbers |
| 04/24/2003 | US20030077579 Diagnostic assay |
| 04/24/2003 | US20030077578 Diagnostic assay |
| 04/24/2003 | US20030077568 Screening drugs; obtain cell with preferential phenotypic profile, incubate with drug, monitor effect on cells |
| 04/24/2003 | US20030077341 Processes of making North American ginseng fractions, products containing them, and use as immunomodulators |
| 04/24/2003 | US20030077294 Proteinaceous material associated with adenylate cyclase activity in cultures of Bordetella pertussis; useful as components of acellular whooping cough vaccines |
| 04/24/2003 | US20030077293 Streptococcus antigens |
| 04/24/2003 | US20030077292 Detection and treatment of cancers of the lung |
| 04/24/2003 | US20030077290 Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use |
| 04/24/2003 | US20030077289 Administering an immune effector cell containing a cell penetrating peptide associated with an antigen for enhancing an immune response in an animal to a disease |
| 04/24/2003 | US20030077287 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 04/24/2003 | US20030077286 A T cell receptor ligand which substantially inhibits at least one T cell effector response evoked by fully active peptide-MHC(major histocompatibility complex) available to respond T cells |
| 04/24/2003 | US20030077285 Methods of diagnosis and treatment by binding p75/airm1 |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077279 Methods for treating vascular disease by inhibiting toll-like receptor-4 |
| 04/24/2003 | US20030077277 Human antibodies that have MN binding and cell adhesion-neutralizing activity |
| 04/24/2003 | US20030077275 Chimeric antibody specific to human CD4 which comprises the variable heavy and light chain sequences of an Old World monkey monoclonal antibody produced against human CD4 and human constant heavy and light domain sequences |
| 04/24/2003 | US20030077273 Methods of treating antibody-mediated pathologies using agents which inhibit CD21 |
| 04/24/2003 | US20030077260 Hybrid matrix implants and explants |
| 04/24/2003 | US20030077257 Administering a dosage of alive larva of nematodes; immunogens treating cancer of the first and second stages, and AIDS-infections |
| 04/24/2003 | US20030077252 Vaccination against plaque forming diseases; inhibiting aggregation of amyloid in mammal and/or to cause disaggregation of amyloid; treating brain disorder, Alzheimer's disease |
| 04/24/2003 | US20030077251 Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
| 04/24/2003 | US20030077248 Treating cancer with a culture product from a non-naturally occurring antigen-presenting cell; polyclonal antibodies expression |
| 04/24/2003 | US20030077247 Chemokines as adjuvants of immune response |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077229 Aqueous polar solvent, active compound, and flavoring agents; propellant-free |
| 04/24/2003 | US20030077228 Polar solvent 30-99.69%, active compound 0.001-60%, and f lavoring agent 0.1-10%; propellant free |
| 04/24/2003 | US20030077227 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/24/2003 | US20030075187 Mixed chimerism and tolerance |
| 04/24/2003 | CA2463996A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | CA2463943A1 Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 04/24/2003 | CA2463927A1 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 04/24/2003 | CA2463672A1 Direct targeting binding proteins |
| 04/24/2003 | CA2463655A1 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | CA2463581A1 Microfluidized leishmania antigen and methods of making and using thereof |
| 04/24/2003 | CA2463492A1 Methods for the treatment of carcinoma |
| 04/24/2003 | CA2463020A1 Use of gp130 activators in diabetic neuropathy |
| 04/24/2003 | CA2463017A1 Method for preparation of single chain antibodies |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2461575A1 Use of peptide vectors to improve the immune response to antigens |
| 04/24/2003 | CA2460132A1 Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent |
| 04/23/2003 | EP1304379A2 Humanised antibody against CD18 |
| 04/23/2003 | EP1304378A1 ARL-2 for fertility control |
| 04/23/2003 | EP1304123A2 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/23/2003 | EP1303620A2 Regulation of human desc1-like serine protease |
| 04/23/2003 | EP1303619A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 04/23/2003 | EP1303613A2 Rescue of canine distemper virus from cdna |
| 04/23/2003 | EP1303612A2 Streptococcus antigens |
| 04/23/2003 | EP1303609A2 G-protein coupled receptors |
| 04/23/2003 | EP1303600A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 04/23/2003 | EP1303591A2 Masp-2, a complement-fixing enzyme, and uses for it |
| 04/23/2003 | EP1303536A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 04/23/2003 | EP1303535A2 Protein complex serving as a vehicle for orally administerable medicaments |
| 04/23/2003 | EP1303533A2 Chimeric peptide immunogens, their preparation and use |
| 04/23/2003 | EP1303303A1 Immunomodulatory human mhc class ii antigen-binding polypeptides |
| 04/23/2003 | EP1303302A2 Use of strains of the parapox ovis virus against organ fibrosis |
| 04/23/2003 | EP1303301A2 Preventing airway mucus production by administration of egf-r antagonists |
| 04/23/2003 | EP1303300A1 Compositions and methods for treatment of candidiasis |
| 04/23/2003 | EP1303299A1 Compositions and methods for enhancing immunogenicity of antigens |
| 04/23/2003 | EP1303293A2 Apo-2l receptor agonist and cpt-11 synergism |
| 04/23/2003 | EP1303287A1 Mhc peptides over-expressed on prostate cancer cells and methods of use |
| 04/23/2003 | EP1303286A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 04/23/2003 | EP0840618B1 Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies |